Shares of pharmaceutical company, Valeant Pharmaceuticals Inc. (VRX - Free Report) fell over 21% after the company reported disappointing third-quarter 2016 results and slashed its sales and earnings outlook for the year.
The company’s adjusted earnings per share of $1.55 missed the Zacks Consensus Estimate of $1.78 by 12.9%. Earnings declined 35.7% year over year on lower product sales.
Total revenue came in at $2.48 billion, missing the Zacks Consensus Estimate of $2.493 billion, and falling 11% year over year. This was mostly due to a decline in overall product sales in its existing business and negative impact from currency as well as divestitures and discontinuations. However, acquisitions completed in 2015 provided some top-line support.
Revenues in the Bausch + Lomb / International segment was $1.16 billion, a rise of 4% year over year due to increased product sales revenues from acquisitions completed in 2015 which offset a decline in product sales revenues from existing businesses
Revenues in the Branded Rx segment were $847 million, almost 23% decline from $1.1 billion in the year-ago quarter mainly due to lower average realized prices resulting from higher managed care rebates in dermatology.
Revenues in the U.S. Diversified Products segment were $471 million a decline of 16.5% year over year due to fall in product sales revenue from existing business.
Research and development expenses were $101 million in the reported quarter, in line with the year-ago quarter.
Selling, General and Administrative costs were $641.5 million compared with $673.7 million in the year-ago quarter, declining almost 5% year over year.
The company slashed its full-year 2016 guidance.
It now expects total revenue to be in the range of $9.55 billion–$9.65 billion, compared with the previous projection of $9.9 billion–$10.1 billion.
Adjusted earnings per share are now expected to be $5.30–$5.50. The previously expected range was $6.60–$7.00.
Adjusted EBITDA is now expected in the $4.25 billion–$4.35 billion range. The previously expected range was $4.80 billion–$4.95 billion.
Valeant currently holds a Zacks Rank #5 (Strong Sell). Some better-ranked stocks in the healthcare sector include Infinity Pharmaceuticals, Inc. (INFI - Free Report) , Bovie Medical Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . Each of the stocks sports a Zacks Rank #1(Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Infinity’s loss estimates narrowed from $3.84 to $3.79 for 2016 over the last 60 days. The company posted positive surprises in all of the four trailing quarters with an average beat of 67.62%.
Bovie’s loss estimates remained unchanged for 2016 but narrowed from 8 cents to 3 cents for 2017 over the last 60 days. The company posted positive surprises in three of four trailing quarters with an average beat of 28.69%.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters with an average beat of 33.14%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>